{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:07:33Z","timestamp":1789459653166,"version":"build-2803163510"},"reference-count":32,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objectives<\/jats:title>\n                    <jats:p>Cryoprecipitated antihemophilic factor (cryoprecipitate), fibrinogen concentrate (FC), and pathogen\u2010reduced cryoprecipitated fibrinogen complex (PR cryoprecipitate) are sources of fibrinogen replacement, and each has advantages and disadvantages in terms of cost, efficacy, safety, and logistics of administration. This study examines the respective utilization frequencies of these different products at institutions in North America and the factors influencing the decision on which one(s) to adopt.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>A survey was distributed via email to contacts for Advancement of Blood and Biotherapies (AABB)\u2010accredited blood banks\/transfusion services. Survey questions covered topics including the availability and usage of FC, cryoprecipitate, and PR cryoprecipitate, as well as the perceived advantages of each product.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 53 responses were received from surveyed institutions (estimated 25% response rate). Over half (31\/53, 58.5%) of respondents exclusively used cryoprecipitate, 30.2% (16\/53) used two sources of fibrinogen replacement, and 7.5% (4\/53) used all three (cryoprecipitate, FC, and PR cryoprecipitate). More than half of the institutions restricted FC to specific indications, primarily for cost containment. The most commonly cited advantages of FC over cryoprecipitate were storage convenience and rapid reconstitution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Surveyed institutions in the United States and Canada primarily use cryoprecipitate for fibrinogen replacement, with variable usage of FC and limited usage of PR cryoprecipitate. The perception of FC being more expensive than cryoprecipitate predominated. Further studies comparing available fibrinogen replacement options would be valuable, particularly with consideration of product acquisition cost, wastage, impacts on utilization of other blood products, and patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/vox.70374","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:29:17Z","timestamp":1789457357000},"source":"Crossref","is-referenced-by-count":0,"title":["Inter\u2010institutional perspectives on usage of fibrinogen replacement therapies in North America"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5491-0694","authenticated-orcid":false,"given":"Cindy","family":"Tay","sequence":"first","affiliation":[{"name":"Department of Pathology, Microbiology and Immunology Vanderbilt University Medical Center  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9101-9326","authenticated-orcid":false,"given":"Laura K.","family":"Dilly","sequence":"additional","affiliation":[{"name":"Department of Pathology University of California San Diego  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2292-3167","authenticated-orcid":false,"given":"Wen","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology Mayo Clinic, Rochester  Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2579-8640","authenticated-orcid":false,"given":"Kerry","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Department of Pathology Beth Israel Deaconess Medical Center  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3091-4175","authenticated-orcid":false,"given":"Hlaing","family":"Tint","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine McGovern Medical School  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3480-7892","authenticated-orcid":false,"given":"Quentin","family":"Eichbaum","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center  Buffalo New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0140-6736(66)92985-0","article-title":"Pool's cryoprecipitate and exhausted plasma in the treatment of von Willebrand's disease and factor\u2010XI deficiency","volume":"288","author":"Bennett E","year":"1966","journal-title":"Lancet"},{"key":"e_1_2_9_3_1","unstructured":"Food and Drug Administration.July 31 2024 approval letter \u2013 FIBRYGA. Available from:https:\/\/www.fda.gov\/media\/180528\/download?attachment. Last accessed 11 Aug 2026."},{"key":"e_1_2_9_4_1","unstructured":"Food and Drug Administration.December 16 2025 biologics license approval letter \u2013 FESILTY. Available from:https:\/\/www.fda.gov\/media\/190222\/download?attachment. Last accessed 11 Aug 2026."},{"key":"e_1_2_9_5_1","unstructured":"Food and Drug Administration.INTERCEPT\u00ae Blood System for cryoprecipitation package insert. Available from:https:\/\/www.fda.gov\/media\/143996\/download. Last accessed 11 Aug 2026."},{"key":"e_1_2_9_6_1","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3390\/pathogens11070744","article-title":"Comparison of bacterial risk in cryo AHF and pathogen\u2010reduced cryoprecipitated fibrinogen complex","volume":"11","author":"Lu T","year":"2022","journal-title":"Pathogens"},{"key":"e_1_2_9_7_1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/17474086.2018.1458610","article-title":"Do we still need cryoprecipitate? Cryoprecipitate and fibrinogen concentrate as treatments for major hemorrhage\u2014how do they compare?","volume":"11","author":"Novak A","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"e_1_2_9_8_1","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1097\/TA.0b013e31828fa3ed","article-title":"Cryoprecipitate use in the PROMMTT study","volume":"75","author":"Holcomb JB","year":"2013","journal-title":"J Trauma Acute Care Surg"},{"key":"e_1_2_9_9_1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/bjh.14804","article-title":"Fibrinogen concentration and use of fibrinogen supplementation with cryoprecipitate in patients with critical bleeding receiving massive transfusion: a bi\u2010national cohort study","volume":"179","author":"McQuilten ZK","year":"2017","journal-title":"Br J Haematol"},{"key":"e_1_2_9_10_1","unstructured":"Food and Drug Administration.Package insert \u2013 FIBRYGA\u00ae. Available from:https:\/\/www.fda.gov\/media\/105864\/download?attachment. Last accessed 11 Aug 2026."},{"key":"e_1_2_9_11_1","unstructured":"Food and Drug Administration.Package Insert \u2013 RiaSTAP. Available from:https:\/\/www.fda.gov\/media\/73604\/download. Last accessed 11 Aug 2026."},{"key":"e_1_2_9_12_1","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/aas.12734","article-title":"Comparing efficacy and safety of fibrinogen concentrate to cryoprecipitate in bleeding patients: a systematic review","volume":"60","author":"Jensen NH","year":"2016","journal-title":"Acta Anaesthesiol Scand"},{"key":"e_1_2_9_13_1","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1111\/trf.15437","article-title":"Fibrinogen concentrate for perioperative bleeding: what can we learn from the clinical trials?","volume":"59","author":"Cushing MM","year":"2019","journal-title":"Transfusion"},{"key":"e_1_2_9_14_1","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1001\/jama.2019.17312","article-title":"Effect of fibrinogen concentrate vs cryoprecipitate on blood component transfusion after cardiac surgery: the FIBRES randomized clinical trial","volume":"322","author":"Callum J","year":"2019","journal-title":"JAMA"},{"key":"e_1_2_9_15_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/voxs.12376","article-title":"Do we need cryoprecipitate in the era of fibrinogen concentrate and other specific factor replacement options?","volume":"13","author":"Wong H","year":"2018","journal-title":"ISBT Sci Ser"},{"key":"e_1_2_9_16_1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/vox.12417","article-title":"Cryoprecipitate AHF vs. fibrinogen concentrates for fibrinogen replacement in acquired bleeding patients\u2013an economic evaluation","volume":"111","author":"Okerberg CK","year":"2016","journal-title":"Vox Sang"},{"key":"e_1_2_9_17_1","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/bja\/aeu158","article-title":"Cryoprecipitate therapy","volume":"113","author":"Nascimento B","year":"2014","journal-title":"Br J Anaesth"},{"key":"e_1_2_9_18_1","unstructured":"National Advisory Committee on Blood and Blood Products.NAC statement on fibrinogen concentrate use in acquired hypofibrinogenemia. Available from:https:\/\/nacblood.ca\/sites\/default\/files\/2025\u201002\/2025\u201002\u201026%20NAC%20Statement%20on%20Fibrinogen%20Concentrate%20Use_0.pdf. Last accessed 11 Aug 2026."},{"key":"e_1_2_9_19_1","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1365-2044.2010.06538.x","article-title":"Blood transfusion and the anaesthetist: management of massive haemorrhage","volume":"65","author":"Thomas D","year":"2010","journal-title":"Anaesthesia"},{"key":"e_1_2_9_20_1","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1111\/trf.18434","article-title":"Survey of cryoprecipitate production and cryoprecipitate and fibrinogen concentrate utilization in North America: variable practices observed from July 2016 to June 2021, The BEST Collaborative Study","volume":"65","author":"Lu W","year":"2025","journal-title":"Transfusion"},{"key":"e_1_2_9_21_1","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1111\/trf.18187","article-title":"Have we reached a new baseline for blood collection and transfusion in the United States? National Blood Collection and Utilization Survey, 2023","volume":"66","author":"McDavid K","year":"2025","journal-title":"Transfusion"},{"key":"e_1_2_9_22_1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/jamasurg.2022.6818","article-title":"Cost\u2010effectiveness of fibrinogen concentrate vs cryoprecipitate for treating acquired hypofibrinogenemia in bleeding adult cardiac surgical patients","volume":"158","author":"Abrahamyan L","year":"2023","journal-title":"JAMA Surg"},{"key":"e_1_2_9_23_1","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/j.jvca.2023.10.031","article-title":"Prospective, randomized study of fibrinogen concentrate versus cryoprecipitate for correcting hypofibrinogenemia in cardiac surgery patients","volume":"38","author":"Ayaganov D","year":"2024","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"e_1_2_9_24_1","doi-asserted-by":"crossref","first-page":"7576","DOI":"10.1182\/blood-2024-208046","article-title":"A single center approach to managing hospitalized patients with quantitative fibrinogen deficiency that cost\u2010saving and maintains high\u2010quality, evidence\u2010based care","volume":"144","author":"Youkhana K","year":"2024","journal-title":"Blood"},{"key":"e_1_2_9_25_1","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/trf.17940","article-title":"How do I implement pathogen reduced cryoprecipitated fibrinogen complex in a tertiary hospital's blood bank","volume":"64","author":"Aidikoff J","year":"2024","journal-title":"Transfusion"},{"key":"e_1_2_9_26_1","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/trf.18344","article-title":"Pathogen\u2010reduced cryoprecipitate: early experiences and inventory management","volume":"65","author":"Webb CB","year":"2025","journal-title":"Transfusion"},{"key":"e_1_2_9_27_1","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/ajcp\/aqae073","article-title":"Implementation and early outcomes with Pathogen Reduced Cryoprecipitated Fibrinogen Complex","volume":"162","author":"Sethapati VR","year":"2024","journal-title":"Am J Clin Pathol"},{"key":"e_1_2_9_28_1","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1111\/trf.15157","article-title":"Efficacy of a new pathogen\u2010reduced cryoprecipitate stored 5\u2009days after thawing to correct dilutional coagulopathy in vitro","volume":"59","author":"Cushing MM","year":"2019","journal-title":"Transfusion"},{"key":"e_1_2_9_29_1","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1111\/trf.16376","article-title":"Effects of pathogen reduction technology and storage duration on the ability of cryoprecipitate to rescue induced coagulopathies in vitro","volume":"61","author":"Thomas KA","year":"2021","journal-title":"Transfusion"},{"key":"e_1_2_9_30_1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1186\/s13063-024-08398-x","article-title":"Trial Of Pathogen\u2010reduced Cryoprecipitate vs. Cryoprecipitated AHF to Lower Operative Transfusions (TOP\u2010CLOT): study protocol for a single center, prospective, cluster randomized trial","volume":"25","author":"Cushing MM","year":"2024","journal-title":"Trials"},{"key":"e_1_2_9_31_1","doi-asserted-by":"crossref","DOI":"10.1177\/10760296241254106","article-title":"Long\u2010term safety analysis of a fibrinogen concentrate (RiaSTAP\u00ae\/Haemocomplettan\u00ae P)","volume":"30","author":"Rahe\u2010Meyer N","year":"2024","journal-title":"Clin Appl Thromb Hemost"},{"key":"e_1_2_9_32_1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1051\/ject\/202153097","article-title":"STS\/SCA\/AmSECT\/SABM update to the clinical practice guidelines on patient blood management","volume":"53","author":"Tibi P","year":"2021","journal-title":"J Extracorp Technol"},{"key":"e_1_2_9_33_1","unstructured":"World Health Organization.WHO recommendation on tranexamic acid for the treatment of postpartum haemorrhage. Available from:https:\/\/www.who.int\/publications\/i\/item\/WHO-RHR-17.21. Last accessed 11 Aug 2026"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.70374","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vox.70374","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.70374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:29:26Z","timestamp":1789457366000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.70374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":32,"alternative-id":["10.1111\/vox.70374"],"URL":"https:\/\/doi.org\/10.1111\/vox.70374","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"vox.70374"}}